glp 1 heart attack GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms The Cardiovascular Biology of Glucagon-like
Description
Other studies find no significant benefits
Many patients restart at their pre-operative dose without issue, but some benefit from a more gradual reintroduction, especially if their surgery was abdominal
Your provider can plan timing and dosing based on your metabolic goals and medical history at that stage
has been a member of advisory boards or has consulted with Boehringer Ingelheim, Eli Lilly & Co., Medtronic, Merck, Sharp & Dohme, NovoNordisk, Pfizer, Regor, Sun Pharma and Structure Therapeutics (ShouTi, Gasherbrum)
PMID 27569426
